- Metabolic Risk/Epidemiology
- Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
-
Soung Won Jeong
-
Diabetes Metab J. 2020;44(5):640-657. Published online October 21, 2020
-
DOI: https://doi.org/10.4093/dmj.2020.0115
-
-
13,831
View
-
582
Download
-
18
Web of Science
-
18
Crossref
-
Abstract
PDF PubReader ePub
- The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents—obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol—are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient.
-
Citations
Citations to this article as recorded by 
- Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan Biomolecules.2025; 15(1): 140. CrossRef - Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder
Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin Current Drug Therapy.2024; 19(1): 20. CrossRef - Ameliorative role of bioactive phytoconstituents targeting obesity associated NAFLD by modulation of inflammation and lipogenesis pathways: a comprehensive review
Pervej Alom Barbhuiya, Saikat Sen, Manash Pratim Pathak Phytochemistry Reviews.2024; 23(4): 969. CrossRef - Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection
Shibing Tao, Shanlan Guo, Nanwei Tong Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2024; 44(8): 642. CrossRef - Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park Diabetes & Metabolism Journal.2023; 47(2): 220. CrossRef - Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee Metabolism.2023; 145: 155612. CrossRef - Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
Willy B Theel, Bianca M Boxma-de Klerk, Femme Dirksmeier-Harinck, Elisabeth FC van Rossum, Danny A Kanhai, Jan A Apers, Bas M van Dalen, Robert J De Knegt, Bojou Neecke, Ellen M van der Zwan, Diederick E Grobbee, Thomas Hankemeier, Janneke Wiebolt, Manuel BMJ Open.2023; 13(7): e070431. CrossRef - Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Youngmin A. Lee, Scott L. Friedman Journal of Internal Medicine.2022; 291(1): 11. CrossRef - Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial
Eugene Han, Ji Hye Huh, Eun Y. Lee, Ji C. Bae, Sung W. Chun, Sung H. Yu, Soo H. Kwak, Kyong S. Park, Byung‐Wan Lee Diabetes, Obesity and Metabolism.2022; 24(4): 752. CrossRef - Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park Obesity.2022; 30(6): 1279. CrossRef - Thyroid diseases and new approaches for their treatment
E. A. Fokina, A. O. Shpakov The Siberian Journal of Clinical and Experimental Medicine.2022; 37(3): 90. CrossRef - Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
Giang Nguyen, So Young Park, Dinh Vinh Do, Dae-Hee Choi, Eun-Hee Cho Endocrinology and Metabolism.2022; 37(6): 918. CrossRef - Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH
Su-Yeon Lee, Sanghwa Kim, Inhee Choi, Yeonhwa Song, Namjeong Kim, Hyung Chul Ryu, Jee Woong Lim, Hyo Jin Kang, Jason Kim, Haeng Ran Seo Cell Death & Disease.2022;[Epub] CrossRef - Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan International Journal of Molecular Sciences.2022; 24(1): 158. CrossRef - Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Hyunmi Kim, Da Som Lee, Tae Hyeon An, Hyun-Ju Park, Won Kon Kim, Kwang-Hee Bae, Kyoung-Jin Oh International Journal of Molecular Sciences.2021; 22(9): 4495. CrossRef - Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong Scientific Reports.2021;[Epub] CrossRef - Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis
João Remí de Freitas Júnior, Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Vitor Massaro Takamatsu Sagae, Gabriel Mayo Vieira de Souza, Guilherme Henrique Peixoto de Oliveira, Sergio A Sánchez-Luna, Thiago Ferreira de Souza, Eduardo Turiani Hourne World Journal of Hepatology.2021; 13(7): 815. CrossRef - The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
Branka Filipovic, Snezana Lukic, Dragana Mijac, Marija Marjanovic-Haljilji, Marko Vojnovic, Jelena Bogdanovic, Tijana Glisic, Natasa Filipovic, Jamal Al Kiswani, Aleksandra Djokovic, Suncica Kapor, Slobodan Kapor, Zoran Bukumiric, Ana Starcevic International Journal of Molecular Sciences.2021; 22(24): 13219. CrossRef
|